Anti-Fibrinolytic Drugs - CIS

The revenue in the Anti-Fibrinolytic Drugs market is forecasted to achieve a staggering US$141.30m in 2025.
This market is expected to exhibit an annual growth rate (CAGR 2025-2029) of 4.16%, leading to a market volume of US$166.30m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, reaching an impressive US$10,320.00m in 2025.
The demand for anti-fibrinolytic drugs in the CIS market is driven by a high prevalence of cardiovascular diseases in the region.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in CIS has been experiencing significant growth over the past few years.

Customer preferences: Patients in CIS countries are increasingly seeking treatment for cardiovascular diseases, which has led to a rise in demand for anti-fibrinolytic drugs. Additionally, the aging population in these countries has also contributed to the growth of the market.

Trends in the market: Russia is the largest market for anti-fibrinolytic drugs in CIS, followed by Ukraine and Kazakhstan. The market is expected to continue to grow due to the increasing prevalence of cardiovascular diseases and the introduction of new drugs. However, the market is also facing challenges such as the high cost of these drugs and the availability of cheaper alternatives.

Local special circumstances: One of the main challenges in the CIS market is the lack of access to healthcare in certain regions. This has led to a disparity in the availability of drugs and treatment options, which has affected the growth of the market. Additionally, the regulatory environment in some countries can also be a challenge for companies operating in the market.

Underlying macroeconomic factors: The economic situation in CIS countries has also played a role in the growth of the anti-fibrinolytic drugs market. The devaluation of local currencies has made imported drugs more expensive, leading to an increase in the demand for locally produced drugs. Additionally, the increasing focus on healthcare and the development of the pharmaceutical industry in these countries have also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.